Rafferty Asset Management LLC lowered its holdings in Geron Co. (NASDAQ:GERN - Free Report) by 15.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,203,583 shares of the biopharmaceutical company's stock after selling 220,421 shares during the period. Rafferty Asset Management LLC owned approximately 0.20% of Geron worth $4,261,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Nvest Financial LLC acquired a new stake in shares of Geron in the fourth quarter worth $693,000. Charles Schwab Investment Management Inc. increased its position in shares of Geron by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,523,864 shares of the biopharmaceutical company's stock worth $16,014,000 after acquiring an additional 73,482 shares in the last quarter. Barclays PLC boosted its stake in shares of Geron by 114.9% in the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after purchasing an additional 694,931 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Geron in the fourth quarter valued at $5,143,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Geron by 8.8% in the fourth quarter. Ameriprise Financial Inc. now owns 3,064,458 shares of the biopharmaceutical company's stock valued at $10,845,000 after purchasing an additional 247,018 shares during the period. Institutional investors and hedge funds own 73.71% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on GERN shares. Barclays restated an "overweight" rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a research note on Thursday, February 27th. Stifel Nicolaus decreased their target price on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. B. Riley downgraded shares of Geron from a "buy" rating to a "neutral" rating and decreased their target price for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Scotiabank downgraded shares of Geron from a "sector outperform" rating to a "sector perform" rating and decreased their target price for the company from $4.00 to $1.50 in a research note on Thursday, May 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $5.00 target price on shares of Geron in a research note on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $5.06.
Get Our Latest Analysis on Geron
Geron Stock Down 2.0%
NASDAQ GERN traded down $0.03 during trading hours on Friday, reaching $1.45. 11,880,486 shares of the company traded hands, compared to its average volume of 11,776,645. Geron Co. has a 12 month low of $1.17 and a 12 month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $923.53 million, a PE ratio of -4.53 and a beta of 0.76. The company has a 50 day moving average of $1.41 and a two-hundred day moving average of $2.53.
Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The firm had revenue of $39.60 million for the quarter, compared to the consensus estimate of $49.88 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm's revenue was up 12927.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.07) EPS. As a group, equities analysts expect that Geron Co. will post -0.25 earnings per share for the current year.
Geron Profile
(
Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
